Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
Clinical trial NCT00769704 · COMPLETED
Trial details
- NCT number
- NCT00769704
- Sponsor
- BioVex Limited
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2009-04-01
- Primary completion
- 2013-02-01
- Enrollment
- 437
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.